True Reply Featured In Neurology Reviews
IMPORTANT: TrueCoin upgraded bounty program and token sale is now live! Click here to register for our referral program and click here to participate in the token sale. Sale ends April 1st, 2018.
In the fall of 2017, the True Reply platform was utilized by the Hereditary Neuropathy Foundation (HNF) to conduct a study on patient pain for their annual Patient-Centered Charcot-Marie-Tooth (CMT) Summit held at the prestigious Massachusetts Institute of Technology.
The True Reply survey was the lead presentation at the summit, and the results were eye-opening for all in attendance. True Reply’s quantitative and qualitative approach helped HNF document patient pain for those suffering from hereditary neuropathies such as CMT. The survey results clearly indicated the gravity of patient pain and alerted health care providers to take immediate action to address this serious issue.
The findings of our study is featured in the March 2018 issue of Neurology Reviews, a prestigious medical publication with an annual readership of over 24,000 medical professionals.
An excerpt of the feature can be seen below:
True Reply Founder Jose Cotto states:
“The ability of True Reply to quantitatively analyze patient responses in real-time while also giving researchers and clinicians access to qualitative data such patient voice tone, cadence and stress levels is a real game changer for Patient Reported Outcome (PRO) studies.”
This press coverage gives True Reply extraordinary exposure to a highly qualified group of medical professionals, who can be potential customers for the platform. The article also touts the future integration of True Reply with two landmark meetings HNF is holding in conjunction with the Federal Drug Administration (FDA) and the Patient Centered Outcome Research Initiative (PCORI) in September of 2018.
Our technology will be integral in helping patients’ voices be heard by decision makers at the highest level of government at these groundbreaking meetings. We are thrilled to help empower HNF and the CMT patient community with our technology to help affect change and accelerate treatments for those afflicted with this debilitating disease.
